Theriva Biologics

TOVX

Market cap $10.6M

TOVX Hedge Fund Activity: Q1 2026 in Review

22 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2026, worth a combined $385K — up 41% from $272K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TOVX positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $49.9K. The largest seller was Morgan Stanley, cutting an estimated $34.8K.

• 22 institutional investors held Theriva Biologics (TOVX) as of Q1 2026, up from 21 in Q4 2025.
• Funds reported $385K of Theriva Biologics stock for Q1 2026, up 41% quarter-over-quarter.
• 5 funds opened new Theriva Biologics positions in Q1 2026 and 3 closed out, a net change of +2 holders.
• The largest Theriva Biologics buyer in Q1 2026 was Virtu Financial, an estimated $49.9K added.
• The largest Theriva Biologics seller in Q1 2026 was Morgan Stanley, an estimated $34.8K sold.

Based on aggregated 13F filings for Q1 2026.